BIOACTIVE PEPTIDE MARKET ANALYSIS

Bioactive peptides are amino acids combined together through a covalent bond. Bioactive peptides are extracted from various natural sources, such as soy, oat, and pulses (chickpea, beans, peas, and lentils) etc.  Thereby providing a variety of health benefits such as better cardiovascular, digestive, endocrine functioning, as well as the immune and nervous system. They are also used in protecting important contents of food and beverages, resulting in decreased oxidation and degradation of the products. Although these peptides are extracted from natural sources, some of them have been designed with the help of chemical synthesis.

Global bioactive peptide market is estimated to be valued at US$ 4,960.4 million in 2022 and is expected to exhibit a CAGR of 9.4% during the forecast period (2022-2030).

Figure 1. Global Bioactive Peptide Market Share (%), by Source, 2022

To learn more about this report, Request sample copy

Increasing preference of plant based collagen peptide and plant based alternatives for egg and seafood is expected to drive growth of the global bioactive peptide market over the forecast period.

Increasing preference and use of plant collagen peptide is expected to drive growth of the global bioactive peptide market over the forecast period. For instance, on June 29, 2022, Vital Proteins, manufactures of  health supplement Product Company, announced the launch of Vital Proteins Lemon Collagen Peptides, containing grass-fed, pasture-raised collagen with an added boost of lemon flavor.

Moreover, in October 2021, Nestle, a food company, announced the launch of plant based alternatives for egg and shrimp (Seafood). The egg alternative was launched under Garden Gourmet vEGGie, the product was vegan, contains soy protein and omega-3 fatty, whereas Nestle expanded its plant-based seafood offerings with the Garden Gourmet Vrimp, which was vegan and made from a combination of seaweed, peas and konjac root.

Figure 2. Global Bioactive Peptide Market Share (%), by Region, 2022

To learn more about this report, Request sample copy

Increasing number of inorganic strategies such as product launch by key players in market is expected to drive growth of the global bioactive peptide market over the forecast period.

Increasing number of inorganic strategies such as product launch by market players is expected to boost the global bioactive peptide market growth over the forecast period. For instance, In November 2018, Nuritas Ltd., a biotechnology company, announced the commercial launch of Peptide which contained anti-inflammatory bioactive peptides. It was the first bioactive ingredient discovered and delivered through artificial intelligence.

Furthermore, in October 2020, Hofseth Biocare, a biotechnology company, announced the launch of ProGo bioactive peptides in the U.S., which helps maintain iron-rich blood, promotes energy utilization, supports red blood cell production, supports gastrointestinal and immune system health and assists in iron absorption from daily diet.

Global Bioactive Peptide Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

Increasing research and development by key players during the pandemic for the treatment of Covid-19 patients is expected to boost the bioactive peptide market growth. For instance, in April 2020, APEPTICO Forschung und Entwicklung GmbH, a biotechnology company, announced that it had signed, together with the solnatide consortium, the Grant Agreement with the European Commission to accelerate the process of making APEPTICO’s proprietary investigational medicinal product (IMP), Solnatide available for medical treatment of patients severely affected by the novel coronavirus 2019 (SARS-CoV-2) disease, COVID-19.

Thus, impact of the Coronavirus (COVID-19) pandemic had positive impact on the global bioactive peptide market during the pandemic.

Global Bioactive Peptide Market: Key Developments

Increasing research and development by key market players in the global bioactive peptide market is expected to drive the global bioactive peptide market over the forecast period. For instance, in September 2020, NeoMatrix Therapeutics, Inc., a clinical-stage company, announced positive topline data from its Phase 1 clinical trial of NMT-cP12, a bioactive peptide for intravenous treatment of burns within 2 to 4 hours of injury.

Furthermore, increasing number of inorganic strategies such as product launch by market players is expected to drive growth of the global bioactive peptide market over the forecast period. For instance, Rousselot, a collagen-based solutions, announced the launch of MSC-certified (Marine Stewardship Council) marine collagen peptides, Peptan, at Beauty & Skincare Formulation Conference 2021, which is made up of wild-caught marine white fish and certified by the Marine Stewardship Council (MSC) to help beauty and nutrition brands differentiate and expand their portfolio in nutria-cosmetics and dietary supplements.

Global Bioactive Peptide Market: Restraint

Increasing number of bioactive peptides alternatives is one of the major factors, which is expected to hamper growth of the global bioactive peptides market over the forecast period, Such as fungi, edible insects, marine macro algae and vegetable proteins.

Other major factor hindering the market growth is lack of documented evidence of safety, lack of complete knowledge regarding the mechanism and functions of bioactive peptides.

Key Players

Major players operating in the global bioactive peptide market include Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd., Naturade, Royal DSM, MYOS RENS Technology Inc., Natural Factors Inc., Valio Oy, GenScript, HELIX BIOMEDIX, Oryn Therapeutics, Selecta Biosciences, NIBEC, vivitide, PEPTIDE INSTITUTE, INC, BCN Peptides, Setlance srl., APEPTICO Forschung und Entwicklung GmbH, and BIONANOPLUS.